Literature DB >> 19885249

Role of physicians in the pharmaceutical industry and clinical research organizations: take more pride in your work.

Lutz Heinemann1, Marcus Hompesch.   

Abstract

Physicians working in biopharmaceutical companies are key components in the successful development of new diagnostic and therapeutic developments. They have a high level of responsibility for the safe performance of clinical studies and for evaluating the efficacy of new potential treatments in patients. Recently, articles in highly ranked scientific journals have challenged this work. This article highlights the shortcomings of those views. In contrast, we document that the majority of the physicians working in the pharmaceutical industry provide extremely high-quality work, in part forced by the rigorous regulatory framework this work has to comply with nowadays. We promote an open (and critical!) discussion while sharing industrial views and opinions with colleagues from academia. Only by a constructive cooperation between both worlds, avoiding a black-and-white view, will we achieve an instrumental and effective way in developing new and affordable diagnostic and therapeutic tools that are truly helpful and affordable for patients. If physicians in the industry take more pride in their work, this would be helpful in fostering such an approach.

Entities:  

Keywords:  CROs; clinical trials; diabetes research

Year:  2008        PMID: 19885249      PMCID: PMC2769751          DOI: 10.1177/193229680800200424

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  3 in total

1.  Regulating academic-industrial research relationships--solving problems or stifling progress?

Authors:  Thomas P Stossel
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

2.  Commercializing clinical trials--risks and benefits of the CRO boom.

Authors:  Miriam Shuchman
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

3.  Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living?

Authors:  Carl Elliott
Journal:  New Yorker       Date:  2008-01-07
  3 in total
  1 in total

1.  Options for taking time out of specialty training.

Authors:  Rachel Byng-Maddick; Karen Walker-Bone
Journal:  Clin Med (Lond)       Date:  2016-08       Impact factor: 2.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.